• Obtain product authorization through Health Canada drug submission processes.

• Receive a Drug Identification Number (DIN) before marketing the medicine in Canada.

• Ensure packaging and labeling comply with bilingual labeling requirements.

• Obtain a Drug Establishment Licence (DEL) for manufacturing, importing, or distributing medicines.

• Maintain Good Manufacturing Practice compliance and quality systems.

• Report adverse drug reactions through the Canada Vigilance Program.

• Maintain distribution records and ensure compliance with Health Canada inspection requirements.

Canada does not operate a national pharmaceutical traceability reporting hub.

Regulatory oversight is managed through several Health Canada systems and databases:

Drug Identification Number (DIN) System
Every authorized medicine receives a unique DIN that identifies the product formulation, manufacturer, and therapeutic classification.

Drug Product Database (DPD)
Public database that provides information about authorized drug products in Canada.

Drug Establishment Licensing (DEL)
Ensures manufacturers, importers, distributors, and wholesalers comply with Good Manufacturing Practices.

Canada Vigilance Program
National system used for adverse drug reaction reporting and safety monitoring.

These systems support regulatory oversight but do not track serialized product movement within the supply chain.

Canada does not require aggregation or serialization for pharmaceutical products.

However, many pharmaceutical manufacturers operating in Canada voluntarily implement serialization and aggregation to support global export requirements, particularly for markets such as the United States, European Union, and GCC countries that mandate serialization.

These voluntary systems typically follow GS1 standards to support supply chain automation and product verification.

• Marketing medicines in Canada without obtaining a Drug Identification Number.

• Failure to provide bilingual labeling in English and French.

• Incomplete documentation during drug submission or establishment licensing.

• Failure to maintain GMP compliance across manufacturing or distribution sites.

• Delayed reporting of adverse drug reactions through the Canada Vigilance Program.